logo
Send Message
Hefei Home Sunshine Pharmaceutical Technology Co.,Ltd
products
products
Home > products > API Active Pharmaceutical Ingredient > Enzalutamide CAS 915087-33-1 API Active Pharmaceutical Ingredient

Enzalutamide CAS 915087-33-1 API Active Pharmaceutical Ingredient

Product Details

Place of Origin: China

Brand Name: Sunshine

Certification: ISO,COA

Model Number: 915087-33-1

Payment & Shipping Terms

Minimum Order Quantity: Negotiation

Price: Negotiation

Packaging Details: Aluminum Foil Bag, Drum

Delivery Time: 7-15DAY

Payment Terms: L/C,D/A,D/P,T/T,Western Union,MoneyGram

Supply Ability: G,KG,TON

Get Best Price
Highlight:

CAS 915087-33-1 Enzalutamide

,

Enzalutamide CAS 915087-33-1

CAS NO::
915087-33-1
Appearance::
White Powder
Molecular Formula::
C21H16F4N4O2S
Molecular Weight::
464.43600
EINECS NO::
805-022-1
MDL NO::
MFCD14155804
CAS NO::
915087-33-1
Appearance::
White Powder
Molecular Formula::
C21H16F4N4O2S
Molecular Weight::
464.43600
EINECS NO::
805-022-1
MDL NO::
MFCD14155804
Enzalutamide CAS 915087-33-1 API Active Pharmaceutical Ingredient

Product Description:

Product Name: Enzalutamide CAS NO: 915087-33-1


Synonyms:

N-methyl-4-[3-(4-cyano-3-trifluoromethylphenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]-2-fluorobenzamide;

4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide;


Chemical & Physical Properties:

Appearance: White powder

Assay :≥99.00%

Density: 1.49

Refractive Index: 1.629


Safety Information:

HS Code: 2933990090

Signal Word: Warning

Hazard Statements: H315; H319; H335

Precautionary Statements:

P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501


MDV 3100 is an a-ndrogen-receptor antagonist that blocks a-ndrogens from binding to the a-ndrogen receptor and prevents nuclear translocation and co-activator recruitment of the ligand-receptor complex. MDV 3100 has also been shown to induce tumor cell apoptosis, and has no agonist activity. MDV 3100 is a candidate for the treatment of castration-resistant prostate cancer.


If you are interested in our products or have any questions, please feel free to contact us!


Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.